SCHEMBL24923945

SCHEMBL24923945

CC(C(=O)OCc1ccccc1)N1C(=O)C=CC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 3/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CDC25B P30305 1/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
USP2 O75604 1/20 0.43
P2RX4 Q99571 1/20 0.43
ELANE P08246 1/20 0.43
GLRA1 P23415 1/20 0.43
IL1RN P18510 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25640385 0.80 ALDH1A1 (0.45) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL30447792 0.80 ALDH1A1 (0.45) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL15394244 0.78 ALDH1A1 (0.40) ALDH1A1KMT2ATDP1LMNAL3MBTL1
SCHEMBL5898757 0.77 PSEN1 (0.45) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL18171810 0.77 ALDH1A1 (0.49) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL12640200 0.76 ALDH1A1 (0.64) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL112859 0.76 ALDH1A1 (0.64) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL939536 0.76 ALDH1A1 (0.64) ALDH1A1SLC6A2SLC6A3KMT2ATDP1
SCHEMBL24923474 0.76 CYP3A4 (0.43) ALDH1A1LMNAHPGDNPC1RAB9A
SCHEMBL11063207 0.75 ALDH1A1 (0.50) ALDH1A1SLC6A2SLC6A3KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230035898-A1 CYCLODEXTRIN PROTEIN DRUG CONJUGATES REGENERON PHARMACEUTICALS, INC. 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230035898-A1 CYCLODEXTRIN PROTEIN DRUG CONJUGATES SDCBP, DDOST, KRTCAP2 ALDH1A1 3824/4885SLC6A2 3717/4885SLC6A3 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.